Laurus Labs Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Satyanarayana Chava

Chief Executive Officer (CEO)

₹186.4m

Compensación total

Porcentaje del salario del CEO	52.9%
Permanencia del CEO	18.3yrs
Participación del CEO	0.05%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Satyanarayana Chava en comparación con los beneficios de Laurus Labs?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	₹2b
Dec 31 2023	n/a	n/a	₹2b
Sep 30 2023	n/a	n/a	₹4b
Jun 30 2023	n/a	n/a	₹6b
Mar 31 2023	₹186m	₹99m	₹8b
Dec 31 2022	n/a	n/a	₹9b
Sep 30 2022	n/a	n/a	₹9b
Jun 30 2022	n/a	n/a	₹8b
Mar 31 2022	₹275m	₹90m	₹8b
Dec 31 2021	n/a	n/a	₹9b
Sep 30 2021	n/a	n/a	₹10b
Jun 30 2021	n/a	n/a	₹11b
Mar 31 2021	₹179m	₹82m	₹10b
Dec 31 2020	n/a	n/a	₹8b
Sep 30 2020	n/a	n/a	₹6b
Jun 30 2020	n/a	n/a	₹4b
Mar 31 2020	₹80m	₹72m	₹3b
Dec 31 2019	n/a	n/a	₹2b
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹923m
Mar 31 2019	₹124m	₹124m	₹938m
Dec 31 2018	n/a	n/a	₹957m
Sep 30 2018	n/a	n/a	₹1b
Jun 30 2018	n/a	n/a	₹1b
Mar 31 2018	₹125m	₹60m	₹2b

Compensación vs. Mercado: La compensación total de Satyanarayana($USD2.24M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD539.67K).

Compensación vs. Ingresos: La compensación de Satyanarayana ha sido consistente con los resultados de la empresa en el último año.

CEO

Satyanarayana Chava (62 yo)

18.3yrs

Permanencia

₹186,442,959

Compensación

Dr. Satyanarayana Chava, PhD, M.sc., has been the Chief Executive Officer of Laurus Labs Limited (also known as Laurus Labs Private Limited and Aptuit Laurus Private Limited) since June 2007 and has been i...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Satyanarayana Chava	CEO & Whole Time Director	18.3yrs	₹186.44m	0.052% ₹ 120.2m
Vantaram Venkata Kumar	CFO & Whole-Time Director	18.3yrs	₹49.65m	0.19% ₹ 433.0m
Lakshmana Rao Chunduru	Head of Quality & Executive Director	6.2yrs	₹33.00m	2.5% ₹ 5.8b
Krishna Chava	Executive VP	less than a year	₹14.61m	0.0038% ₹ 9.0m
Malempati Venu Rao	Independent Non-Executive Chairman	7yrs	₹2.50m	0.0071% ₹ 16.7m
Ravindranath Kancherla	Non-Executive Independent Director	7yrs	₹2.45m	sin datos
Aruna Bhinge	Non-Executive Independent Director	7.7yrs	₹2.60m	0.0032% ₹ 7.6m
Rajesh Chandy	Non-Executive Independent Director	7.8yrs	₹3.86m	sin datos
Karnam Sekar	Additional Independent Director	less than a year	sin datos	sin datos

7.0yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 540222 se considera experimentada (7.6 años de antigüedad promedio).

Laurus Labs Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Laurus Labs Limited, Annual General Meeting, Jul 11, 2024

Laurus Labs Limited Approves Board Changes

Insufficient new directors

Insufficient new directors

Insider recently sold ₹7.9m worth of stock

Insider recently sold ₹3.2m worth of stock

Recent updates

Final dividend reduced to ₹0.40

Laurus Labs Limited, Annual General Meeting, Jul 11, 2024

Full year 2024 earnings: EPS misses analyst expectations

Laurus Labs Limited Approves Board Changes

Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024

Upcoming dividend of ₹0.40 per share at 0.4% yield

Price target increased by 7.2% to ₹371

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023

Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023

Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.

Investor sentiment improves as stock rises 16%

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million.

Upcoming dividend of ₹1.20 per share at 0.6% yield

Price target decreased by 11% to ₹382

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to ₹470

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023

Laurus Labs Limited announced that it expects to receive INR 38.998 million in funding from Ethan Energy India Private Limited

Price target decreased to ₹561

Insufficient new directors

Consensus EPS estimates fall by 14%

Upcoming dividend of ₹0.80 per share

Price target decreased to ₹574

Laurus Labs Limited Approves Interim Dividend for the Financial Year 2022-2023, Payable on or After November 15, 2022

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q2, 2023 Results on Oct 21, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q1, 2023 Results on Jul 27, 2022

Investor sentiment deteriorated over the past week

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of ₹1.20 per share

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Laurus Labs Limited to Report Q4, 2022 Results on Apr 28, 2022

Consensus revenue estimates fall by 14%

Price target decreased to ₹563

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of ₹0.80 per share

Second quarter 2022 earnings released: EPS ₹3.76 (vs ₹4.53 in 2Q 2021)

Investor sentiment deteriorated over the past week

Insider recently sold ₹7.9m worth of stock

Insider recently sold ₹3.2m worth of stock

Insider recently sold ₹3.6m worth of stock

Insider recently sold ₹1.0m worth of stock

Price target increased to ₹561

First quarter 2022 earnings released: EPS ₹4.50 (vs ₹3.21 in 1Q 2021)

Price target increased to ₹506

Laurus Labs Limited Receives the License to Manufacture and Market 2-Deoxy-D-Glucose (2DG) in India

Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020)

Insider recently bought ₹4.0m worth of stock

Insider recently sold ₹35m worth of stock

Consensus EPS estimates increase to ₹21.57

Price target increased to ₹430

Upcoming dividend of ₹0.80 per share

Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020)

Laurus Labs Limited Approves Third Interim Dividend, Payable on or After May 19, 2021

Investor sentiment improved over the past week

Insider recently sold ₹1.5m worth of stock

Price target raised to ₹399

Insider recently sold ₹1.9m worth of stock

Insider recently bought ₹3.0m worth of stock

Revenue and earnings beat expectations